Biogen reported Q2 2023 results with a revenue of $2,456 million and GAAP diluted EPS of $4.07. The company is focused on shifting resources to high-value creation areas, including investments in prioritized pipeline and new product launches, alongside cost-saving initiatives.
Second quarter revenue was $2,456 million.
GAAP diluted EPS was $4.07, while non-GAAP diluted EPS was $4.02.
LEQEMBI was launched in the U.S.
A new 'Fit for Growth' program is expected to generate approximately $1 billion in gross operating expense savings.
Biogen is reaffirming its full year 2023 guidance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance